Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden

Gunnar Johansson, Po Chun Peng, Po Yuan Huang, Hsiung Fei Chien, Kuo Tai Hua, Min Liang Kuo, Chin Tin Chen, Ming Jen Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Neurofibromatosis type 1 (NF1) is the most common tumor predisposition disorder affecting 1/3500 worldwide. Patients are at risk of developing benign (neurofibromas) and malignant peripheral nerve sheath tumors (MPNST). The AXL receptor tyrosine kinase has been implicated in several kinds of cancers, but so far no studies have investigated the role of AXL in NF1 related tumorigenesis. Recently, the soluble fraction from the extracellular domain of AXL (sAXL) has been found in human plasma, and its level was correlated to poor prognosis in patients with renal cancer. Compared to normal human Schwann cells, a significantly high expression level of AXL was found in three of the four MPNST cell lines and two of the three primary MPNST tissues. Similarly, the level of sAXL in conditioned media corresponded to the protein and mRNA levels of AXL in the MPNST cell lines. Furthermore, in two different human MPNST xenograft models, the human sAXL could be detected in the mouse plasma. Its level was proportionate to the size of the xenograft tumors, while no human sAXL was detect prior to the formation of the tumors. Treatment with a newly developed photodynamic therapy, prevented further tumor growth and resulted in drastically reduced the levels of sAXL compared to that of the control group. Finally, the level of sAXL was significantly increased in patients with plexiform tumors compared to patients with only dermal neurofibromas, further supporting the role of sAXL as a marker for NF1 related tumor burden.

Original languageEnglish
Pages (from-to)e115916
JournalPLoS One
Volume9
Issue number12
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Neurofibromatosis 1
Biomarkers
Tumor Burden
Neurilemmoma
Tumors
biomarkers
neoplasms
peripheral nerves
Neurofibroma
Neoplasms
Tumor Cell Line
Heterografts
Cells
Kidney Neoplasms
Schwann Cells
Photochemotherapy
Receptor Protein-Tyrosine Kinases
Conditioned Culture Medium
cell lines
kidney neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Johansson, G., Peng, P. C., Huang, P. Y., Chien, H. F., Hua, K. T., Kuo, M. L., ... Lee, M. J. (2014). Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. PLoS One, 9(12), e115916. https://doi.org/10.1371/journal.pone.0115916

Soluble AXL : a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. / Johansson, Gunnar; Peng, Po Chun; Huang, Po Yuan; Chien, Hsiung Fei; Hua, Kuo Tai; Kuo, Min Liang; Chen, Chin Tin; Lee, Ming Jen.

In: PLoS One, Vol. 9, No. 12, 01.01.2014, p. e115916.

Research output: Contribution to journalArticle

Johansson, G, Peng, PC, Huang, PY, Chien, HF, Hua, KT, Kuo, ML, Chen, CT & Lee, MJ 2014, 'Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden', PLoS One, vol. 9, no. 12, pp. e115916. https://doi.org/10.1371/journal.pone.0115916
Johansson, Gunnar ; Peng, Po Chun ; Huang, Po Yuan ; Chien, Hsiung Fei ; Hua, Kuo Tai ; Kuo, Min Liang ; Chen, Chin Tin ; Lee, Ming Jen. / Soluble AXL : a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. In: PLoS One. 2014 ; Vol. 9, No. 12. pp. e115916.
@article{337ba3fe5877403cab74ecf92c9e7852,
title = "Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden",
abstract = "Neurofibromatosis type 1 (NF1) is the most common tumor predisposition disorder affecting 1/3500 worldwide. Patients are at risk of developing benign (neurofibromas) and malignant peripheral nerve sheath tumors (MPNST). The AXL receptor tyrosine kinase has been implicated in several kinds of cancers, but so far no studies have investigated the role of AXL in NF1 related tumorigenesis. Recently, the soluble fraction from the extracellular domain of AXL (sAXL) has been found in human plasma, and its level was correlated to poor prognosis in patients with renal cancer. Compared to normal human Schwann cells, a significantly high expression level of AXL was found in three of the four MPNST cell lines and two of the three primary MPNST tissues. Similarly, the level of sAXL in conditioned media corresponded to the protein and mRNA levels of AXL in the MPNST cell lines. Furthermore, in two different human MPNST xenograft models, the human sAXL could be detected in the mouse plasma. Its level was proportionate to the size of the xenograft tumors, while no human sAXL was detect prior to the formation of the tumors. Treatment with a newly developed photodynamic therapy, prevented further tumor growth and resulted in drastically reduced the levels of sAXL compared to that of the control group. Finally, the level of sAXL was significantly increased in patients with plexiform tumors compared to patients with only dermal neurofibromas, further supporting the role of sAXL as a marker for NF1 related tumor burden.",
author = "Gunnar Johansson and Peng, {Po Chun} and Huang, {Po Yuan} and Chien, {Hsiung Fei} and Hua, {Kuo Tai} and Kuo, {Min Liang} and Chen, {Chin Tin} and Lee, {Ming Jen}",
year = "2014",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0115916",
language = "English",
volume = "9",
pages = "e115916",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Soluble AXL

T2 - a possible circulating biomarker for neurofibromatosis type 1 related tumor burden

AU - Johansson, Gunnar

AU - Peng, Po Chun

AU - Huang, Po Yuan

AU - Chien, Hsiung Fei

AU - Hua, Kuo Tai

AU - Kuo, Min Liang

AU - Chen, Chin Tin

AU - Lee, Ming Jen

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Neurofibromatosis type 1 (NF1) is the most common tumor predisposition disorder affecting 1/3500 worldwide. Patients are at risk of developing benign (neurofibromas) and malignant peripheral nerve sheath tumors (MPNST). The AXL receptor tyrosine kinase has been implicated in several kinds of cancers, but so far no studies have investigated the role of AXL in NF1 related tumorigenesis. Recently, the soluble fraction from the extracellular domain of AXL (sAXL) has been found in human plasma, and its level was correlated to poor prognosis in patients with renal cancer. Compared to normal human Schwann cells, a significantly high expression level of AXL was found in three of the four MPNST cell lines and two of the three primary MPNST tissues. Similarly, the level of sAXL in conditioned media corresponded to the protein and mRNA levels of AXL in the MPNST cell lines. Furthermore, in two different human MPNST xenograft models, the human sAXL could be detected in the mouse plasma. Its level was proportionate to the size of the xenograft tumors, while no human sAXL was detect prior to the formation of the tumors. Treatment with a newly developed photodynamic therapy, prevented further tumor growth and resulted in drastically reduced the levels of sAXL compared to that of the control group. Finally, the level of sAXL was significantly increased in patients with plexiform tumors compared to patients with only dermal neurofibromas, further supporting the role of sAXL as a marker for NF1 related tumor burden.

AB - Neurofibromatosis type 1 (NF1) is the most common tumor predisposition disorder affecting 1/3500 worldwide. Patients are at risk of developing benign (neurofibromas) and malignant peripheral nerve sheath tumors (MPNST). The AXL receptor tyrosine kinase has been implicated in several kinds of cancers, but so far no studies have investigated the role of AXL in NF1 related tumorigenesis. Recently, the soluble fraction from the extracellular domain of AXL (sAXL) has been found in human plasma, and its level was correlated to poor prognosis in patients with renal cancer. Compared to normal human Schwann cells, a significantly high expression level of AXL was found in three of the four MPNST cell lines and two of the three primary MPNST tissues. Similarly, the level of sAXL in conditioned media corresponded to the protein and mRNA levels of AXL in the MPNST cell lines. Furthermore, in two different human MPNST xenograft models, the human sAXL could be detected in the mouse plasma. Its level was proportionate to the size of the xenograft tumors, while no human sAXL was detect prior to the formation of the tumors. Treatment with a newly developed photodynamic therapy, prevented further tumor growth and resulted in drastically reduced the levels of sAXL compared to that of the control group. Finally, the level of sAXL was significantly increased in patients with plexiform tumors compared to patients with only dermal neurofibromas, further supporting the role of sAXL as a marker for NF1 related tumor burden.

UR - http://www.scopus.com/inward/record.url?scp=84990944636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990944636&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0115916

DO - 10.1371/journal.pone.0115916

M3 - Article

C2 - 25551830

AN - SCOPUS:84990944636

VL - 9

SP - e115916

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

ER -